Acelity

Acelity

Acelity was formed in 2014 when Apax Partners merged Kinetic Concepts Inc. (KCI) with LifeCell and Systagenix, creating a wound-care and regenerative-medicine portfolio with nearly four decades of operating history tracing back to KCI's 1976 founding in San Antonio. The transaction consolidated three distinct therapeutic categories — negative-pressure wound therapy, advanced wound dressings, and biologics for soft-tissue repair — under a single corporate platform. KCI alone had pioneered the V.A.C. therapy system, which became a standard of care in treating complex wounds, while LifeCell's acellular dermal matrices were widely used in hernia repair and breast reconstruction (per public record). Apax Partners acquired KCI for $6.3 billion in 2011 and built Acelity into a top-three global wound-care pure-play before the 3M exit. Acely's investment posture centered on manufacturing and commercializing proprietary medical devices rather than funding external startups. Its core asset classes included negative-pressure wound therapy systems, advanced silicone and foam dressings, and biologic meshes sourced from porcine and human tissue. The company's operating footprint spanned North America, Europe, and Asia, with direct sales infrastructure in more than 90 countries. Named portfolio brands under the Acelity umbrella included the V.A.C.ULTA and V.A.C.Via negative-pressure systems, the PROMOGRAN PRISMA collagen dressings, and the STRATTICE reconstructive tissue matrix. Acelity also maintained a dedicated surgical solutions division that sold into acute-care hospitals and ambulatory surgery centers, competing directly with Smith & Nephew, Mölnlycke, and ConvaTec. At the time of the 3M transaction, Acelity employed thousands of professionals across its San Antonio headquarters and manufacturing facilities in the United States, United Kingdom, and Ireland. The company was fully owned by a consortium led by Apax Partners alongside Canada Pension Plan Investment Board and the Public Sector Pension Investment Board, who together captured the 2019 exit to 3M. The acquisition closed in October 2019 for $4.3 billion in cash plus roughly $2.4 billion in assumed debt, marking one of the largest medtech take-privates turned strategic exits of the decade (per Bloomberg, 2019). 3M subsequently integrated Acelity into its Medical Solutions division, retiring the Acelity brand and operating the assets as 3M Health Care's wound-management and biologics unit. Acelity's structural differentiator was its scale-and-scope argument: it was privately held by institutional investors yet operated with the manufacturing depth and regulatory infrastructure of a public medtech company, running GMP-compliant biologics plants and Class II/III device lines simultaneously. This hybrid posture — a PE-owned manufacturer with full vertical integration from R&D through hospital sales — allowed its sponsors to capture operational improvements that strategic acquirers would pay a premium for. The 3M deal validated the thesis, and the firm's components now function as a fully integrated division inside a Fortune 500 conglomerate.